Depakote ER Drug Interactions: What to Avoid and What to Tell Your Doctor

Depakote ER (divalproex sodium) has a significant number of important drug interactions — some that can make it less effective, some that can cause dangerous toxicity, and some that affect the levels of other medications you are taking. This is one of the most interaction-prone medications in common use, making it critical to keep your prescriber and pharmacist fully informed about everything you take.

Why Does Depakote ER Have So Many Drug Interactions?

Valproic acid is highly protein-bound (90%+) in the bloodstream and is metabolized primarily by the liver through multiple pathways including glucuronidation and CYP enzymes. This means it interacts with many drugs that are also highly protein-bound (competing for binding sites), drugs that affect liver enzymes, and drugs processed by similar metabolic pathways.

Major Interactions: Avoid or Use With Extreme Caution

Carbapenem antibiotics (meropenem, ertapenem, imipenem/cilastatin): This is the most clinically critical interaction. Carbapenems can reduce serum valproate levels by 60–100% within 24 hours, potentially leading to complete loss of seizure control or mood destabilization. If a patient on Depakote ER needs antibiotic therapy, a non-carbapenem alternative should be selected whenever possible.

Adagrasib (Krazati): Adagrasib is a CYP2C9 inhibitor that increases valproate levels. Avoid co-administration or closely monitor valproate levels and for toxicity if co-administration is unavoidable.

Interactions That Increase the Risk of Serious Side Effects

Topiramate (Topamax): Co-administration increases the risk of hyperammonemia (high blood ammonia) and hyperammonemic encephalopathy — even in patients with normal liver function. Patients on both medications should be monitored for confusion, lethargy, or vomiting.

Fosphenytoin/phenytoin: A complex bidirectional interaction. Valproate displaces phenytoin from protein binding, temporarily increasing free phenytoin levels (risk of phenytoin toxicity). Valproate also inhibits phenytoin metabolism. Additionally, fosphenytoin increases risk of hyperammonemia when combined with valproate. Close monitoring of both drugs is required.

Lamotrigine (Lamictal): Valproate inhibits the glucuronidation of lamotrigine, approximately doubling lamotrigine blood levels. When starting valproate in a patient already on lamotrigine, the lamotrigine dose must be halved to prevent toxicity and serious skin reactions (Stevens-Johnson syndrome). Conversely, stopping valproate requires lamotrigine dose increases.

Aspirin (salicylates): Aspirin displaces valproate from protein binding sites, increasing the free (active) fraction of valproate. This can increase both the effect and side effects of Depakote ER. Avoid high-dose aspirin in patients on Depakote ER unless clinically necessary.

Interactions That Reduce Depakote ER Effectiveness

Rifampin (Rifadin): A potent enzyme inducer that significantly increases valproate clearance, reducing blood levels. Patients starting rifampin for tuberculosis while on Depakote ER may need valproate dose increases.

Ritonavir (Norvir) and antiretrovirals: HIV medications, particularly ritonavir, can reduce valproate levels significantly. Patients living with HIV and on valproate should have their levels monitored more frequently.

Estrogen-containing medications: Oral contraceptives and other estrogen-containing medications may reduce valproate levels in some patients, potentially reducing seizure control. Women on both medications should have valproate levels monitored.

Phenobarbital and primidone: These enzyme-inducing anticonvulsants can reduce valproate levels while valproate may increase phenobarbital levels — requiring monitoring of both.

Interactions That Affect Other Drugs (Valproate Raises Other Drug Levels)

Amitriptyline and nortriptyline (TCAs): Valproate inhibits the metabolism of these tricyclic antidepressants, increasing their blood levels and the risk of TCA side effects (anticholinergic effects, cardiac conduction changes). Dose reduction of the TCA may be needed.

Zidovudine (AZT/Retrovir): Valproate inhibits the glucuronidation of zidovudine, significantly increasing its blood levels and the risk of toxicity. Dose adjustments and monitoring are required.

Nimodipine (calcium channel blocker): Valproate can increase nimodipine levels, potentially enhancing its blood pressure-lowering effects.

Food and Supplement Interactions

Alcohol: Alcohol increases CNS depression when combined with Depakote ER. Avoid alcohol or limit use significantly.

St. John's Wort: May reduce valproate levels through enzyme induction. Avoid in patients on Depakote ER.

L-carnitine: Valproate can deplete carnitine levels. L-carnitine supplementation may be recommended by some providers, particularly in children and patients at higher risk of valproate toxicity.

What to Tell Your Doctor and Pharmacist

Before starting Depakote ER, give your prescriber and pharmacist a complete list of all your medications including:

All prescription medications (including antibiotics, antivirals, anticonvulsants, mood stabilizers, antidepressants, birth control)

Over-the-counter medications including aspirin and aspirin-containing products

All vitamins, herbal supplements, and natural products (especially St. John's Wort)

The Bottom Line

Depakote ER is an effective medication but requires careful attention to drug interactions. The most dangerous interactions involve carbapenems (which can eliminate valproate's effect), lamotrigine (where valproate doubles lamotrigine levels), and co-administration with other CNS drugs. Always use a single pharmacy when possible so your pharmacist can screen for interactions automatically. For information on side effects, see our guide on Depakote ER side effects. If you need help finding Depakote ER, visit medfinder.